Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 12;13:997482. doi: 10.3389/fimmu.2022.997482

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Feng, Xu, Cinquina, Wu, Zhang, Sun, Chen, Tian, Song, Pinz, Wada, Jiang, Hanes, Ma and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CD4-IL15/IL15sushi CAR T cells improve symptoms in Patient 2 with mycosis fungoides lymphoma. (A) Leg skin appearance with erythema and swelling before treatment with CD4-IL15/IL15sushi CAR T cells. (B) Leg skin appearance 2 weeks after treatment shows some improvement. (C) Leg skin appearance after 4 weeks after treatment show even further improvement. (D) H&E staining of skin biopsy before treatment show numerous lymphocytic infiltrates. (E) H&E staining of skin biopsy days after infusion of CD4-IL15/IL15sushi CAR T cells show less lymphocytic cells in the skin. (F) CD4 expression of malignant T cells in skin biopsy before treatment. (G) Diminished CD4 expression in skin biopsy days after infusion. (H) CD3+CD4+, including the malignant cells, reduced to undetectable levels by 24 days after CD4-IL15/IL15sushi CAR T cell therapy. (I) Therapy led to rapid suppression of B cells to undetectable levels by 6 days after treatment. (J) Expansion of NK cells 1 month after therapy. (K) Expansion of CD3+CD8+ cells in the first month post-infusion.